Amondys 45

Chemical Namecasimersen
Dosage FormInjection (intravenous; 100 mg/2 mL)
Drug ClassOligonucleotides
SystemMusculoskeletal
CompanySarepta Therapeutics
Approval Year2021

Indication

  • Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.
Last updated on 7/27/2022

More on this drug: Clinical Trials

Document TitleYearSource
Amondys 45 (casimersen) Prescribing Information.2021Sarepta Therapeutics, Inc. Cambridge, MA

Have we missed a study, or would you like to comment on a study?